Travere Therapeutics (TVTX) Change in Receivables (2014 - 2026)

Travere Therapeutics (TVTX) has 13 years of Change in Receivables data on file, last reported at $7.2 million in Q1 2026.

• Quarterly Change in Receivables changed 0.29% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.8 million (up 138.83% YoY) and the FY2025 annual result came in at $27.8 million, up 363.62% from the prior year.
• Change in Receivables climbed to $7.2 million in Q1 2026, from -$27.8 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $44.2 million in Q3 2025 to a low of -$27.8 million in Q4 2025.
• A 5-year average of $3.1 million and a median of $2.0 million in 2024 frame the typical range for Change in Receivables.
• The widest YoY moves for Change in Receivables: up 5940.36% in 2025, down 1502.17% in 2025.
• Tracing TVTX's Change in Receivables over 5 years: stood at $6.0 million in 2022, then soared by 32.73% to $8.0 million in 2023, then slumped by 75.1% to $2.0 million in 2024, then tumbled by 1502.17% to -$27.8 million in 2025, then jumped by 125.97% to $7.2 million in 2026.
• The last three Change in Receivables figures came in at $7.2 million (Q1 2026), -$27.8 million (Q4 2025), and $44.2 million (Q3 2025), per Business Quant data.